On the first anniversary of what Donald Trump had previously called “Liberation Day,” the former US President announced a fresh set of aggressive trade measures, including up to 100% tariffs on certain patented pharmaceutical imports and revised duties on industrial metals such as steel, aluminium, and copper. The move comes after parts of the earlier global tariff framework were struck down by the US Supreme Court earlier this year, prompting the administration to introduce a new structure aimed at protecting domestic manufacturing and recovering lost tariff revenue.
“These measures are necessary to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
~Donald Trump, President of the United States
The latest tariff package is being viewed as one of the most significant trade announcements in recent months, especially as it directly targets global pharmaceutical companies and industrial exporters. The timing is also crucial, coming amid rising global energy prices and geopolitical tensions that are already affecting supply chains and manufacturing costs worldwide.
Pharmaceutical Companies Face Up to 100% Import Duty:
Under the new executive order, pharmaceutical companies importing patented or branded medicines into the United States may face tariffs of up to 100% if they do not agree to the administration’s pricing and domestic manufacturing requirements. Companies that sign the “most favoured nation” pricing deal and actively move production to the US can avoid the tariff completely.
“Taxes on cutting-edge medicines will increase costs and could jeopardise billions in US investments.”
~Stephen J. Ubl, CEO, Pharmaceutical Research and Manufacturers of America (PhRMA
Industry bodies have raised concerns that the measure could increase costs for healthcare providers and potentially disrupt the pharmaceutical supply chain, despite the administration’s argument that it will reduce long-term dependency on foreign drug manufacturing.
Steel, Aluminium and Copper Tariffs Also Reworked:
Alongside pharmaceutical duties, Trump also announced significant changes to tariffs on steel, aluminium, and copper imports. The revised framework reduces tariffs on several derivative metal products to 25%, while products containing less than 15% metal content by weight may receive exemptions.
“The revised metals duty structure is expected to support domestic producers but may raise costs for downstream manufacturers.”
~Reuters Markets Desk
According to analysts, the updated tariff system would help domestic metal producers, but it might also raise the cost of raw materials for industries including consumer goods, infrastructure, and automobiles.
Global Trade and Supply Chains May Feel the Impact:
The announcement is expected to have a wider impact on global trade flows, especially for countries exporting medicines and industrial metals to the US. Multinational drugmakers may now accelerate plans to expand American production facilities, while metal exporters may need to reassess pricing and supply contracts.
“The tariff reset could reshape sourcing decisions for healthcare and industrial sectors worldwide.”
— Reuters Global Markets Team
Market players are now keeping a careful eye on how manufacturing and pharmaceutical firms react to the change in regulation. The action supports Trump’s larger campaign for home manufacturing and economic nationalism, issues that continue to influence conversations about international trade.
